Robbins Farley Makes New $4.96 Million Investment in AstraZeneca PLC $AZNCF

Robbins Farley bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 25,137 shares of the company’s stock, valued at approximately $4,958,000. AstraZeneca comprises approximately 2.2% of Robbins Farley’s investment portfolio, making the stock its 19th biggest holding.

Other large investors have also recently made changes to their positions in the company. Athena Wealth Management LLC bought a new position in shares of AstraZeneca in the first quarter worth about $1,911,000. AdvisorNet Financial Inc purchased a new position in AstraZeneca in the 1st quarter worth about $2,361,000. Defined Wealth Management LLC bought a new stake in AstraZeneca during the 1st quarter valued at about $255,000. SVB Wealth LLC purchased a new stake in AstraZeneca in the 1st quarter valued at about $556,000. Finally, Bell Investment Advisors Inc purchased a new stake in AstraZeneca in the 1st quarter valued at about $39,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

Shares of AZNCF stock opened at $187.10 on Tuesday. The company’s 50-day simple moving average is $187.10 and its two-hundred day simple moving average is $186.10. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.